Relmada Therapeutics Strengthens Board of Directors with Appointment of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
News
iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis
Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Harvard Pilgrim Health Care And Ride Health Collaborate To Provide Health Care-Related Transportation For Medicare Members In Two States
CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea
Funding represents 51st CARB-X Award, and 2nd CARB-X Award for VenatoRx
Palvella Therapeutics Commences Phase 3 Portion of Phase 2/3 Pivotal Study of PTX-022 in Pachyonychia Congenita
Fast Track-designated program aims to be first targeted therapy addressing root cause of chronically debilitating rare genetic disease
Tmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients
– Strategic collaboration may support future trials with CAR T-cell therapy
– Tmunity will use Oncora Medical’s proprietary analytical tools to access real world data and innovate clinical trial design
pH Pharma and Immunome Enter into Collaboration and License Agreement to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates in Oncology
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
Findings show that REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures